circulating fgf21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in chinese循环fgf21水平逐步提高早期结束阶段的慢性肾脏疾病和与肾功能有关.pdfVIP

Circulating FGF21 Levels Are Progressively Increased from the Early to End Stages of Chronic Kidney Diseases and Are Associated with Renal Function in Chinese 1,2. 3. 1. 1 1 1 1 Zhuofeng Lin , Zhihong Zhou , Yanlong Liu , Qi Gong , Xinxin Yan , Jian Xiao , Xiaojie Wang , Shaoqiang Lin1, Wenke Feng1,5, Xiaokun Li1,4* 1 School of Pharmacy, Wenzhou Medical College, Zhejiang, China, 2 School of Pharmacy, Jinan University, Guanghzou, China, 3 Division of Kidney, the 2nd Affiliated Hospital, Wenzhou Medical College, Zhejiang, China, 4 The Key Lab of Pathobiology, National Ministry of Education, Jilin University, Changchun, China, 5 School of Medicine, University of Louisville, Louisville, Kentucky, United States of America Abstract Background: Fibroblast growth factor 21 (FGF21) is a hepatic hormone involved in the regulation of lipid and carbohydrate metabolism. This study aims to test the hypothesis that elevated FGF21 concentrations are associated with the change of renal function and the presence of left ventricular hypertrophy (LVH) in the different stages of chronic kidney disease (CKD) progression. Methodology/Principal Findings: 240 subjects including 200 CKD patients (146 outpatients and 54 long-term hemodialytic patients) and 40 healthy control subjects were recruited. All CKD subjects underwent echocardiograms to assess left ventricular mass index. Plasma FGF21 levels and other clinical and biochemical parameters in all subjects were obtained based on standard clinical examination methods. Plasma FGF21 levels were significantly increased with the development of CKD from early- and end-stage (P,0.001 for trend), and significantly higher in CKD subjects than those in h